About Ibd

What if we knew which patients would have severe Crohn’s disease or ulcerative colitis? And which wouldn’t? How about if we could tell which drug would work best in which patient? Knowing these things would change how inflammatory bowel disease (IBD) is diagnosed and treated. Plus, more importantly: it would improve lives. Dr Andres Hurtado-Lorenzo, Vice President of Translational research and IBD Ventures at the Crohn's and Colitis Foundation explains biomarkers and how they may play into the future of how IBD is diagnosed, managed, and treated. Resources: Crohn’s & Colitis Foundation:https://www.crohnscolitisfoundation.org/ IBD Plexus:https://www.crohnscolitisfoundation.org/research/current-research-initiatives/ibd-plexus/about RISK Study:https://www.crohnscolitisfoundation.org/research/current-research-initiatives/pediatric-risk-stratification IBD Ventures:https://www.crohnscolitisfoundation.org/research/grants-fellowships/entrepreneurial-investing/portfolio Olink: https://www.olink.com Foundation for